Please Wait
Applying Filters...
menu
    • menu
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Oct 2024: Lundbeck acquires Longboard for US$ 2.6 bn; molecular glue degrader tech witnesses dealmaking

    Stock Recap
    #PipelineProspector

    Menu

    Hyaluronidase

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 428Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Certificate Holder Certificate No. Substance Issue Date Status Type End Date Substance No.
    28/10/2024 BBI Solutions
    United Kingdom
    		 BBI ENZYMES SA (PTY) LTD Cape Town ZA R1-CEP 2001-085 - Rev 02 Hyaluronidase, Product codes: 081231, 081236, 081239, 081240, 081242, 081244, 081245, 081246 and 081247 2010-06-01 Valid TSE 912
    28/10/2024 Bioindustria L.I.M. Spa
    Italy
    		 BIOINDUSTRIA L.I.M. S.P.A. Novi Ligure IT R1-CEP 2001-068 - Rev 00 Hyaluronidase 2007-04-04 Suspended by EDQM GMP non-compliance TSE 2023-03-30 912